WHO Raises Concern Over Acute Shortage of Weight-Loss Medications
Less than 10% of individuals that would benefit from GLP-1 drugs including Wegovy can access them, caution the World Health Organization as it issues its inaugural recommendations on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for increased and just access to these injectable treatments.
Based on estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The new guidance recognises that obesity is a long-term condition that can be addressed with holistic and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant barriers to widespread access to the jabs that can aid individuals in losing significant weight, explains the organization.
Weight-Loss Drug Scarcity
Even under the current most optimistic case, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – less than 10% of the global need, as stated by the WHO.
The advice urges countries and companies to widen availability, through strategies including voluntary licensing.
The intellectual property rights on the active ingredient – the primary component of the drug Wegovy – is set to lapse in several countries in 2026.
The Way Obesity Drugs Function
The injections replicate a body's own hormone to reduce digestion speed, reduce hunger and enhance satiety so individuals eat less.
Individuals usually begin shedding pounds in the initial weeks of commencing the once-weekly jabs.
Research points to users may put most of the weight back on a year later of discontinuing the medication, as their typical food cravings resume.
Being overweight or obese raises your likelihood for developing diseases, like diabetes, heart disease, stroke, and some malignancies.
Excess weight concerns people in every country and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.
